Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.
about
Tuberculosis vaccines: beyond bacille Calmette-GuerinCross-subtype immunity against avian influenza in persons recently vaccinated for influenzaSafety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South AfricaA new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteersThe re-emergency and persistence of vaccine preventable diseasesHost immune responses to mycobacterial antigens and their implications for the development of a vaccine to control tuberculosisVaccines against tuberculosis: where are we and where do we need to go?Vaccines for TB: Lessons from the Past Translating into Future PotentialsPrime-boost approaches to tuberculosis vaccine developmentFusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primatesComparing adjuvanted H28 and modified vaccinia virus ankara expressingH28 in a mouse and a non-human primate tuberculosis modelProspects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis?Quest for correlates of protection against tuberculosisAnnulling a dangerous liaison: vaccination strategies against AIDS and tuberculosisSafety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West AfricaProspective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic reviewSerum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85AEffect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adultsTh1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85AA Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adultsVariable host-pathogen compatibility in Mycobacterium tuberculosisSafety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trialEstablishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testingHIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine developmentThe TB pandemic: an old problem seeking new solutions.Chronic helminth infections may negatively influence immunity against tuberculosis and other diseases of public health importance.Novel vaccination strategies against tuberculosis.Permutations of time and place in tuberculosisRecombinant Mycobacterium bovis BCG as an HIV vaccine vector.Identification of antigens specific to non-tuberculous mycobacteria: the Mce family of proteins as a target of T cell immune responses.Toward novel vaccines against tuberculosis: current hopes and obstacles.Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis.Cellular immune responses to nine Mycobacterium tuberculosis vaccine candidates following intranasal vaccination.Development of new tuberculosis vaccines: a global perspective on regulatory issuesBoosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trialsPersistence of the immune response induced by BCG vaccination.Improved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boostingrBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vectorEnhanced and enduring protection against tuberculosis by recombinant BCG-Ag85C and its association with modulation of cytokine profile in lung.CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination.
P2860
Q22242669-5E97D473-C716-4981-BC5E-20AE85C92041Q24647051-66AD920D-78FE-4914-B3EC-6F9D8BC7018FQ24647137-E1C9FB4A-FF40-43F4-9E04-FE727AFBA4B4Q24657992-45D18F93-6468-4C3F-A44D-53010DA49895Q26796600-93DF6A05-B752-443F-AE6C-6AC4BB330BBDQ26863391-C9386BF3-0334-4A48-A690-7B619F1F43D8Q26992233-58794AAE-0920-45B5-841C-4117365B80C8Q26996673-3E96AD51-8BB0-443A-9B31-5F7DA34465D6Q27024526-B0741692-B769-49F8-9FB5-202657B9E0A0Q27306708-63C9429A-4BC0-4321-A3FE-69545B3789EFQ27309052-826B5CD5-10C5-440D-97A9-526535CC263FQ28083377-E4441CA3-F978-47C1-B657-6689C4FBC03CQ28084282-33DA5B93-AC3E-40FB-8B39-078C43C924E7Q28243702-EC4BE018-2021-4901-B05C-2BE7186C4EA7Q28473318-82ED4E06-8B70-4F9E-9D70-14D16CC066E9Q28485174-B143F636-A1FC-4144-A40C-8E6BC941CEE0Q28649845-3C5A4836-6814-477C-A260-9D6A9EA9AB1CQ28728311-56743D37-1E29-4DF9-B5F7-F3EE878BBEA3Q28740954-96C6735F-6C52-4AF0-A511-C77EB4E50882Q28742450-A78B90C2-B41E-46DD-BB43-BE9F90F615FDQ28768257-72674977-93B7-4851-BCE0-A9CF2398DA3BQ29620144-278371F8-4F4E-473F-B267-26A3C93A1F6CQ30227121-476DC1F9-BB46-44AA-9CAB-2E188D6C1917Q30355260-20D01EE7-F436-4689-820B-E6F039AA6566Q30360726-152190F5-41F0-4FE3-A2D8-99F95033ACC8Q30362107-DA2A773E-983D-4261-9BBC-60BE7C97E7F2Q30363188-14E71FF4-5E3E-4642-BA52-4723F23C284DQ30378562-AF7F4F08-EE79-4218-B0E0-CA13966B9271Q30387447-EFD9AFE1-1D5B-422A-A1E9-48D33E1D0C4DQ30408875-EDD3D230-5EE7-4EFE-9F26-1D0F95CD2159Q30484783-0B3E241A-28BD-44F0-9724-4CA1BFC99C20Q30945400-9639F733-9C32-4830-B2CB-DB9A97D7541EQ31028998-09B1C75B-26B0-4EBF-A478-6C793B3452D6Q33293376-257A3F6A-E902-4F01-BA03-95D00B1E49DCQ33303660-1015BE99-FC2B-4C50-A365-CFB6686FAF8CQ33316559-F5BA7672-BD4B-4026-8148-9F7E38F5B03EQ33324374-69F39AE2-586B-44DE-B465-032C31684F89Q33386020-02D437FD-8010-4C14-8386-AB5610BDE5D7Q33389187-D0AAE9CF-A480-4DA8-BF9D-8BD3DFFB7936Q33428562-43281A9E-2D68-4E71-9F85-C52C35709925
P2860
Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Recombinant modified vaccinia ...... obacterial immunity in humans.
@ast
Recombinant modified vaccinia ...... obacterial immunity in humans.
@en
Recombinant modified vaccinia ...... obacterial immunity in humans.
@nl
type
label
Recombinant modified vaccinia ...... obacterial immunity in humans.
@ast
Recombinant modified vaccinia ...... obacterial immunity in humans.
@en
Recombinant modified vaccinia ...... obacterial immunity in humans.
@nl
prefLabel
Recombinant modified vaccinia ...... obacterial immunity in humans.
@ast
Recombinant modified vaccinia ...... obacterial immunity in humans.
@en
Recombinant modified vaccinia ...... obacterial immunity in humans.
@nl
P2860
P50
P356
P1433
P1476
Recombinant modified vaccinia ...... obacterial immunity in humans.
@en
P2093
Ansar A Pathan
Clare R Sander
P2860
P2888
P304
P356
10.1038/NM1128
P407
P577
2004-10-24T00:00:00Z